Compare Incyte Corporation (INCY) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NICE Ltd — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while NICE Ltd trades at $99.98 (market cap $5.91B). The key difference: Incyte Corporation is far larger — about 3.9× NICE Ltd's market cap, and Incyte Corporation is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| INCY | NICE | |
|---|---|---|
Market Cap | $23.11B | $5.91B |
Sector | Health | Technology |
52-Week High | $118.52 | $170.37 |
52-Week Low | $67.38 | $83.15 |
Enterprise Value | $19.13B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
NICE trades at $101.34, up 1.19% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a 17.57% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights AI-driven customer engagement expansions, including a partnership with Banco do Brasil announced on July 14, 2026.
The outlook is positive with a consensus price target of $124.88, implying significant upside. Risks include a projected decline in net income for 2026 and competitive pressures in the technology sector. The absence of sell ratings from analysts underscores underlying strength, but investors should monitor execution against future earnings expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
